Ranbaxy announces plans for future biosimilars

Yesterday, Ranbaxy Laboratories announced it's plans to have three biosimilars on the market in India by 2015. The drugs will mainly be used to treat cancer. Their goal is to become serious competitors of Sandoz and Teva, and plan to do that by gaining biosimilars experience with approval of their biosimilars in India then expanding to the United States and Europe. They currently have one approved biosimilar on the market - a copy of Neupogen, an Amgen drug.Find out more at Reuters.

At the Business of Biosimilars and Generic Drugs this September 10-12 in Boston, Volker Schellenberger, CSO, AMUNIX will be on hand to present "Improve and Approve: Boost the Safety and Convenience of Biobetters, and Navigate the New Regulatory Environment." In this discussion, Schellenberger will look at the current pathway to biosimilar approval, which will be required for the drugs to enter the market. For more information on this year's program, download the agenda. If you'd like to join us in Boston, register today and mention code XP1786BLOG to save 10% off the standard rate.

Do you think that gaining biosimilars knowledge in India before moving into the US Market will benefit companies like Ranbaxy? Why or why not?

Share this article with your social network, just click below to share now!

Share |